4 x Epirubicin, Cyclophosphamide, Followed by 4 x Docetaxel Versus 6 x CMF / 6 x CEF

Exclusion Criteria

• •Polyneuropathy
• •Creatinin (serum) \> 1,4 mg/dl; Bilirubin (serum) \> 2,0 mg/dl
• •Cardia dysfunction, ejection fraction \< lower normal value of each institution
• •Hematopoeitic insufficiency: leucocytes \< 3,5 G/l, thrombocytes \< 100 G/l
• •second malignant neoplasia, except curatively treated basalioma of the skin
• •Surgery before more the six weeks (42 days)
• •Concurrent pregnancy; patients of childbearing potential must implement a highly effective (less than 1% failure rate) non-hormonal contraceptive measures during the study treatment
• •Breast feeding woman
• •Sequential breast cancer
• •Reasons indicating risk of poor compliance
• •Patients not able to consent